🍽️ methazolamide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Reduction of Intraocular Pressure: Methazolamide helps lower intraocular pressure by decreasing the production of aqueous humor in the eye. By reducing intraocular pressure, the medication can slow down the progression of optic nerve damage and vision loss associated with glaucoma.

  2. Treatment of Glaucoma: Methazolamide is primarily prescribed to individuals with open-angle glaucoma, a common form of glaucoma where the drainage angle of the eye remains open but fluid drainage is inadequate. By reducing intraocular pressure, methazolamide helps manage the condition and prevent further vision loss.

  3. Adjunctive Therapy: In addition to being used as a standalone treatment for glaucoma, methazolamide may also be prescribed as adjunctive therapy alongside other medications or interventions to further lower intraocular pressure and improve treatment outcomes.

  4. Side Effects: Like all medications, methazolamide can cause side effects, although not everyone will experience them. Common side effects may include gastrointestinal disturbances (such as nausea, vomiting, diarrhea), frequent urination, loss of appetite, taste alterations, and tingling sensations in the extremities. Less commonly, methazolamide may cause more serious side effects such as electrolyte imbalances, metabolic acidosis, blood disorders, and kidney stones.

  5. Contraindications: Methazolamide is contraindicated in individuals with a known allergy to sulfonamide medications, severe kidney or liver disease, adrenal gland failure, and certain electrolyte imbalances. It should be used with caution in individuals with respiratory or metabolic acidosis, severe chronic obstructive pulmonary disease (COPD), or electrolyte abnormalities.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of methazolamide,(prescription) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by methazolamide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Coprococcus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Lachnospira eligens species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of methazolamide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.2 0.3 -0.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.1
Allergies 0.2 -0.2
Allergy to milk products 0.1 0.1
Alzheimer's disease 0.1 0.5 -4
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.1 3
Ankylosing spondylitis 0 0.1 0
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0.2 0.2
Asthma 0.1 -0.1
Atherosclerosis 0.1 0.3 -2
Atrial fibrillation 0.5 0.5
Autism 0.6 0.6 0
Barrett esophagus cancer 0 0
Bipolar Disorder 0.1 0.5 -4
Brain Trauma 0.1 -0.1
Carcinoma 0.2 0.1 1
Celiac Disease 0 0.1 0
Cerebral Palsy 0 0.2 0
Chronic Fatigue Syndrome 0.5 0.9 -0.8
Chronic Kidney Disease 0.4 -0.4
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.4 -3
Chronic Urticaria (Hives) 0 0
Coagulation / Micro clot triggering bacteria 0 0.3 0
Colorectal Cancer 0.3 0.3
Constipation 0 0.1 0
Coronary artery disease 0.1 0.3 -2
COVID-19 0.2 1.1 -4.5
Crohn's Disease 0.5 0.6 -0.2
cystic fibrosis 0.1 -0.1
deep vein thrombosis 0.3 -0.3
Depression 0.5 1.2 -1.4
Dermatomyositis 0 0
Eczema 0.1 -0.1
Endometriosis 0.3 0.1 2
Epilepsy 0 0
Fibromyalgia 0.1 0.6 -5
Functional constipation / chronic idiopathic constipation 0.3 0.4 -0.33
gallstone disease (gsd) 0.1 0.1 0
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 0
Generalized anxiety disorder 0.3 -0.3
Glioblastoma 0 0
Gout 0.3 -0.3
Graves' disease 0.1 -0.1
Halitosis 0 0
Hashimoto's thyroiditis 0.1 0.1
Hidradenitis Suppurativa 0 0
Histamine Issues 0.1 0.1
hypertension (High Blood Pressure 0.2 0.4 -1
Hypothyroidism 0.3 -0.3
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 0.1 1 -9
Insomnia 0 0.1 0
Intelligence 0.3 0.3
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.2 0.1 1
Liver Cirrhosis 0.6 0.6 0
Long COVID 0.7 0.8 -0.14
Low bone mineral density 0.4 -0.4
Lung Cancer 0.1 -0.1
Mast Cell Issues / mastitis 0 0.4 0
ME/CFS with IBS 0 0.6 0
ME/CFS without IBS 0.2 0.2
Metabolic Syndrome 0.6 0.6 0
Mood Disorders 0.9 1.2 -0.33
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.2 0.3 -0.5
Multiple system atrophy (MSA) 0.1 -0.1
neuropathic pain 0 0
Neuropathy (all types) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0.4 0
Obesity 0.6 0.5 0.2
obsessive-compulsive disorder 0.3 0.3 0
Osteoarthritis 0 0.1 0
Osteoporosis 0.1 0.1
pancreatic cancer 0 0
Parkinson's Disease 0.3 0.8 -1.67
Polycystic ovary syndrome 0.1 0.3 -2
Postural orthostatic tachycardia syndrome 0.3 -0.3
Psoriasis 0.2 0.4 -1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.6 0.4 0.5
Rosacea 0.1 0.1 0
Schizophrenia 0.4 0.5 -0.25
scoliosis 0.3 0.2 0.5
Sjögren syndrome 0 0
Sleep Apnea 0.4 0.4 0
Small Intestinal Bacterial Overgrowth (SIBO) 0 0
Stress / posttraumatic stress disorder 0.1 0.4 -3
Systemic Lupus Erythematosus 0.3 0.2 0.5
Tic Disorder 0.1 0.1
Type 1 Diabetes 0.4 0.2 1
Type 2 Diabetes 0.6 0.6 0
Ulcerative colitis 0 0.4 0
Unhealthy Ageing 0.3 0.4 -0.33

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]